Impax Laboratories Inc

Impax Laboratories — Investor Presentation (March 2006)

28 slides from Impax Laboratories's investor presentation, Mar 30, 2006

  1. Slide 1: IMPAX Laboratories, Inc. March 2006

    CID IMPAX March 2006 v1 IMPAX Laboratories, [HE

  2. Slide 2: Safe Harbor statement

    “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. In particular,

  3. Slide 3: Company Overview

    Technology based specialty pharmaceutical company Applying oral drug delivery technology and formulation expertise to the development of generic and branded pharmaceutical products Experienced senior management team Strong product portfolio Strong strategic partners Brand strategy offers potential l

  4. Slide 4: Product Portfolio

    Approximately 113 generic products approved, pending or under development - targeting over $30 billion in US product sales 32 Approved applications 20 Applications pending at FDA 4 ANDAs with Tentative Approval Approximately 61 more under development Additional products and/or strengths Additionally

  5. Slide 5: R&D Highlights

    2005 - Received 6 approvals from FDA Tentative Approval for a generic version of: Final Approvals for generic versions of: 5 R&D Highlights Ditropan XL Dantrium Agrylin Rimadyl (a veterinary product) Glucophage XR 750 mg OxyContin 10, 20 & 40 mg

  6. Slide 6: Commercial Highlights

    2005 - Launched 6 new products Includes generic versions of: 6 Commercial Highlights Claritin-D 24 hour OxyContin 80mg CR Tablets Dantrium Capsules Agrylin Capsules Rimadyl Caplets (a veterinary product) OxyContin 10, 20 & 40mg CR Tablets

  7. Slide 7: Drug Delivery Capabilities

    7 Multiple delivery vehicles Applying new and existing drug delivery technologies to create new product opportunities Developing and patenting new concepts and oral controlled release technologies Over 120 employees in our R&D effort Drug Delivery Capabilities (18 approved ANDAs utilize our drug del

  8. Slide 8: Development Strategy

    Target limited competition environment Generic Controlled Release- large, rapidly growing market Specialty- technically challenging projects, barriers to entry, or other selected market opportunities Brand Targeting drugs used in treating CNS disorders Focusing on improved versions of marketed compo

  9. Slide 9: Development Strategy: Outsourced Development

    Outsourced Development Selected Generic Projects 21 development projects outsourced Utilizing 6 off-shore companies Provides Lower cost of development Increased development capacity 9 Development Strategy

  10. Slide 10: Generic Projects: Current Status

    Current Status *US Market size, millions of US$ $18,604 61 $15,188 32 $3,416 29 Under Development $7,501 20 $6,797 9 $704 11 Pending at FDA 10 Generic Projects $26,105 $21,985 $4,120 Total Market* Qty Market* Qty Market* Qty Category Total Controlled Release Specialty Group

  11. Slide 11: Paragraph IV Filing Summary (22 total)

    Paragraph IV Filing Summary (22 total) *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 1 :Paragraph IV cert. & notice filed 4Q02. Products in Teal are marketed. White background means TA/FA rec’d. Initial Filing Est. Filing Orde

  12. Slide 12: Paragraph IV Filing Summary

    Paragraph IV Filing Summary *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 2 --Paragraph IV certification and notice filed 3Q05. Note 3 --May be first to file on 15 mg strength. Initial Filing Est. Filing Order** Generic of* IM

  13. Slide 13: Paragraph IV Litigation Status Summary: Resolved or Not Sued

    Paragraph IV Litigation Status Summary (22 total filed) Litigation Resolved or Not Sued (14 projects) 13 Generic Projects Fenofibrate 54 &160mg Tabs Loratadine & PSE 5/120mg ER 12hr S.E. Amphetamine ER Undisclosed Metformin 750mg ER Loratadine 10mg OD Carprofen 25,75,100mg Fenofibrate 67,134,200mg C

  14. Slide 14: Paragraph IV Litigation Status Summary

    Paragraph IV Litigation Status Summary (22 total filed) Litigation Status Project 14 Generic Projects Discovery stage. No trial date scheduled. Methylphenidate ER Not yet sued. Venlafaxine ER Discovery stage. No trial date scheduled. Bupropion 150 &300mg ER (XL) Favorable judgment entered based on p

  15. Slide 15: Strategic Alliances for Generic Projects: Teva

    Signed June 2001 First product shipped 1Q 2004 12 Rx products 11 filed to date 11 disclosed 40 Methylphenidate 18,27,36,54 mg ER Fexofenadine/PSE 60/120 mg ER Oxybutynin 5,10,15 mg ER Bupropion 150, 300 mg ER (XL) 15 Commercial Strategy Strategic Alliances for Generic Projects Teva (Rx Partners) Ome

  16. Slide 16: Strategic Alliances for Generic Projects: Dava

    Signed November 2005 Ten year exclusive agreement Payments of $60 million to be received over five years Profit split First product shipped 4Q 2005 Products Licensed: Oxycodone 10, 20 40 mg ER Oxycodone 80 mg ER 16 Commercial Strategy Strategic Alliances for Generic Projects Dava (Rx Partners)

  17. Slide 17: Shire Settlement

    Settlement agreements signed January 2006 Provide for dismissal of all lawsuits and claims related to Impax Paragraph IV filings for generic versions of Shire’s Adderall ® XR Market entry date no later than January 1, 2010 Earlier launch if another generic launches prior to January 1, 2010 Exclusive

  18. Slide 18: Strategic Alliances: Over The Counter Loratadine

    Status Loratadine Products Date Partner 18 Commercial Strategy Strategic Alliances for Generic Projects Over The Counter (OTC) Launched 2Q04 as Triaminic brand. Terminated 2Q05 ODT (Ped) Dec 2001 Novartis Launched ODT 4Q04 Launched D-24 1Q05 ODT & D-24 Jun/Jul 2004 Leiner Launched 1Q03 as Claritin D

  19. Slide 19: Brand Projects

    Targeting improved versions of existing chemical entities Reduced risk and expense associated with development as compared to NCE development. Reduced time of development as compared to NCE development Utilize development and drug delivery expertise Improve patient compliance and outcomes 19 Brand P

  20. Slide 20: Brand Projects: Focus on CNS drugs

    Focus on Central Nervous System (CNS) drugs Rapidly growing therapeutic area Focus on CNS disease states, including movement disorders such as Parkinson’s disease. These movement disorders are frequently treated by the approximately 8,300 practicing neurologists, of which about 3,500 write the major

  21. Slide 21: Brand Projects: Unmet needs in Parkinson's treatment

    Despite being the standard for treating Parkinson’s Disease, existing levodopa therapy does not meet certain needs: Delayed or unpredictable “on” Motor fluctuation and dyskinesias Pill burden True delivery of continuous dopaminergic stimulation 21 Brand Projects

  22. Slide 22: Brand Projects: VADOVA

    VADOVA TM (carbidopa-levodopa) is formulated with the goal of meeting one of these unmet needs by allowing a reduction in pill burden. 22 Brand Projects

  23. Slide 23: Brand Projects: VADOVA NDA status

    The effective date of acceptance of the VADOVA NDA by FDA was May 3, 2005. The application contained a Paragraph III certification which prevents any approval from becoming effective prior to June 16, 2006. “Non-approvable” letter received from FDA March 3, 2006. Response preparation and meeting req

  24. Slide 24: Strategic Alliances for Branded Projects: Shire Carbatrol

    Signed January 2006 Three year exclusive agreement Payments of $40 million to be received over three years to provide promotional services Target audience – Neurologists Details to begin 3Q 2006 Promoted Product: Carbatrol ® (carbamazepine extended release) 24 Commercial Strategy Strategic Alliances

  25. Slide 25: Significant Milestones

    6 10 0 11 9 8 1 2 Approvals (Total) 1 6 8 8 8 8 Applications Filed *Includes amendments to two previously filed applications—not included in 2005 applications filed 25 Significant Milestones Vedco, Dava 3* 2005 IND filings Shire Leiner Andrx / Teva Wyeth, Schering Teva, Novartis -- Strategic Allianc

  26. Slide 26: Cash and Debt Balances

    26 Dec-04 Jun-05 Dec-05 Cash and Investments 78,826 50,251 56,077 Senior Debt 12,966 5,447 5,396 Convertible Subordinated Debt 95,000 75,000 75,000 Total Senior and Convertible Debt 107,966 80,447 80,396 (000s and unaudited) Cash and Debt Balances

  27. Slide 27: Highlights

    Experienced management with strong industry knowledge and technical expertise Broad base of drug delivery technology, formulation and development expertise Strong product portfolio Strong strategic partners – Teva, Wyeth, Schering, Leiner, Dava and Shire Branded product strategy offers potential lon

  28. Slide 28: Thank you for your interest in IMPAX Laboratories, Inc

    Thank you for your interest in IMPAX Laboratories, Inc 28

Impax Laboratories — Investor Presentation (March 2006) on 6ix